Arcturus Therapeutics Holdings

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ARCT and other ETFs, options, and stocks.

About ARCT

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. 

CEO
Joseph E. Payne
CEOJoseph E. Payne
Employees
111
Employees111
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2013
Founded2013
Employees
111
Employees111

ARCT Key Statistics

Market cap
205.93M
Market cap205.93M
Price-Earnings ratio
-3.08
Price-Earnings ratio-3.08
Dividend yield
Dividend yield
Average volume
487.14K
Average volume487.14K
High today
$7.54
High today$7.54
Low today
$7.12
Low today$7.12
Open price
$7.40
Open price$7.40
Volume
565.23K
Volume565.23K
52 Week high
$24.17
52 Week high$24.17
52 Week low
$5.85
52 Week low$5.85

Stock Snapshot

Arcturus Therapeutics Holdings(ARCT) stock is priced at $7.25, giving the company a market capitalization of 205.93M. It carries a P/E multiple of -3.08.

During the trading session on 2026-03-05, Arcturus Therapeutics Holdings(ARCT) shares reached a daily high of $7.54 and a low of $7.12. At a current price of $7.25, the stock is +1.8% higher than the low and still -3.8% under the high.

Trading activity shows a volume of 565.23K, compared to an average daily volume of 487.14K.

The stock's 52-week range extends from a low of $5.85 to a high of $24.17.

The stock's 52-week range extends from a low of $5.85 to a high of $24.17.

ARCT News

TipRanks 1d
Arcturus Therapeutics price target lowered to $25 from $72 at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $25 from $72 by removing the LUNAR-COVID Vaccine Global...

TipRanks 2d
Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)

Reports Q4 revenue $7.2M, consensus $14.32M. “Arcturus continues to progress its rare disease therapeutic portfolio. We look forward to aligning with regulators...

Analyst ratings

75%

of 12 ratings
Buy
75%
Hold
25%
Sell
0%

People also own

Based on the portfolios of people who own ARCT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.